About Nalfon (fenoprofen calcium) USP

There is a Difference...

6,786 patients participated in clinical trials of Nalfon with less than 2% discontinuing due to Gastrointestinal related side effects.  Of these patients, 188 were followed for one year. 1

Nalfon has extensive healthcare provider use with over 42 years of prescribing. 2

Nalfon is not combined with a Proton Pump Inhibitor (PPI) or H2 Antagonist which could potentially lead to additional safety concerns in long term use.

Nalfon is 99% bound to plasma protein for greater Cox-2 inhibition.

Nalfon has no absorption interference when given with commonly prescribed antacids containing aluminum and magnesium hydroxide.  

Nalfon begins to relieve pain in as little as 15-30 minutes.

Relieving Mild to Moderate Pain, OA and RA...

Nalfon is indicated:

  • For relief of mild to moderate pain in adults.
  • For relief of the signs and symptoms of rheumatoid arthritis.
  • For relief of the signs and symptoms of osteoarthritis.

Important Safety Information


What is NALFON (fenoprofen calcium)?

NALFON is a nonsteroidal, anti-inflammatory, antiarthritic drug.  Carefully consider the potential benefits and risks of NALFON and other treatment options before deciding to use NALFON.  Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.  After observing the response to initial therapy with NALFON, the dose and frequency should be adjusted to suit an individual patient's needs.  Total daily dosage should not exceed 3,200 mg.  NALFON may be administered with meals or with mile.  The smallest dose that yields acceptable control should be employed.


NALFON is indicated for relief of mild to moderate pain in adults and for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.  

Cardiovascular Risk

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.  This risk may increase with duration of use.  Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (See Warnings in Prescribing Information).
  • NALFON is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (See Warnings in Prescribing Information).

Gastrointestinal Risk

  • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal.  These events can occur at any time during use and without warning symptoms.  Elderly patients are at greater risk for serious gastrointestinal events (See Warnings in Prescribing Information).